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Abstract
Background: Several studies have been published in the literature on the diagnostic accuracy of NT-pro-BNP for
pleural effusions from heart failure in the last decade. The purpose of our study was to perform a systematic
review and meta-analysis on the diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions of cardiac
origin.
Methods: MEDLINE, EMBASE, PapersFirst, and the Cochrane collaboration and the Cochrane Register of controlled
trials were searched. All searches were inclusive as of March 2010. Studies were only included if the absolute
number of true-positive, false-negative, true-negative, and false-positive observations were available, and the
“reference standards” were described clearly. Two investigators independently reviewed articles and extracted data.
Quality was assessed with the Quality Assessment for Diagnostic Accuracy Studies (QUADAS). The bivariate model
for diagnostic meta-analysis was used to obtain a pooled sensitivity and a pooled specificity.
Results: Ten studies (total number of patients 1120) were included in the meta-analysis. The average pleural fluid
NT-pro-BNP level in effusions of cardiac origin was 6140 pg/mL. The pooled sensitivity and specificity of all studies
combined was 94% (95% CI: 90-97) and 94% (95% CI: 89-97) respectively. The pooled positive likelihood ratio was
15.2 (95% CI: 8.1-28.7) and the pooled negative likelihood ratio was 0.06 (95% CI: 0.03-0.11). The area under the
ROC curve was 0.98 (95% CI: 0.96-0.99) and the diagnostic odds ratio was 246 (95% CI: 81-745).
Conclusions: Pleural fluid NT-pro-BNP is a very useful biomarker with high diagnostic accuracy for distinguishing
pleural effusions of cardiac origin.
Background
Pleural effusions arising from heart failure are usually
discriminated from other causes based on clinical criteria
in association with biochemical analysis, particularly the
discrimination of transudates versus exudates, most com-
monly using Light’s criteria [1]. The sensitivity of Light’s
criteria for identifying exudative pleural effusions is very
high (98%)[2], however the criteria’s ability to exclude
transudative effusions is low[3]. As a result, heart failure
associated pleural effusions can be misclassified as exu-
dates using Light’s criteria, particularly after diuretics
have been used. One study showed that 28% (5 of 18)
patients with pleural effusions from congestive heart
failure (CHF) were misclassified as exudative effusions
using Light’s criteria[4]. A diagnostic dilemma often
arises when CHF-associated pleural effusions are misclas-
sified as exudates which can then lead to the use of more
expensive and sometimes invasive tests to diagnose the
etiology of the effusion. A non-invasive and inexpensive
strategy to discriminate pleural effusions of a cardiac ori-
gin would be beneficial in such circumstances.
Serum brain natriuretic peptide (BNP) or the amino-
terminal fragment N-terminal pro-brain natriuretic
peptide (NT-pro-BNP) have an established role in the
diagnosis, management, and prognosis of patients with
CHF[5]. BNP, also known as B-type natriuretic peptide,
is a 32 amino acid polypeptide secreted by the ventricles
of the heart in response to excessive stretching of cardi-
omyocytes[6]. BNP is co-secreted along with a 76 amino
acid polypeptide, NT-pro-BNP, which is biologically
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minutes whereas of NT-pro-BNP is 1-2 hours[8]. BNP
binds to atrial natriuretic factor receptors leading to a
decrease in systemic vascular resistance and central
venous pressure, and an increase in natriuresis[6].
Several studies have been published in the literature
on the diagnostic accuracy of NT-pro-BNP for pleural
effusions from heart failure. The purpose of our study
was to perform a systematic review and meta-analysis
on the diagnostic accuracy of pleural fluid NT-pro-BNP
for pleural effusions of cardiac origin.
Methods
The systematic review and meta-analysis was performed
according to the recently published recommendations
and checklist of the PRISMA statement[9].
Searches were conducted on MEDLINE (inception-March
2010); EMBASE (inception-March 2010), PapersFirst (incep-
tion-March 2010), and the Cochrane collaboration and the
Cochrane Register of controlled trials for relevant studies.
T h ef o l l o w i n gk e yt e r m sw e r eu s e d :‘pleural fluid’ or ‘pleural
effusion’ AND ‘brain natriuretic peptide’ or ‘B-type natriure-
tic peptide’ or ‘BNP’, ‘pro-BNP’ or ‘NT-pro-BNP’ or ‘amino-
terminal pro-BNP’ or ‘congestive heart failure’ or ‘heart fail-
ure’ or ‘CHF’. All searches were limited to ‘humans’.W e
identified additional studies by searching the bibliographies
of retrieved articles. Two independent reviewers (SJ and JS)
performed the literature search. Studies relevant to the diag-
nostic value of NT-pro-BNP for pleural effusions of cardiac
origin were included if the following criteria were met:
pleural fluid NT-pro-BNP was used for diagnosing pleural
effusions of cardiac origin; and a 2 × 2 contingency table
could be formulated from the available data. Studies that
used BNP or other biomarkers were excluded.
All studies that appeared to fit the inclusion criteria
were identified for full review by two reviewers (SJ and
JS). Each reviewer independently selected studies for
inclusion in the review. Disagreement between the two
extracting authors was resolved by consensus.
The methodological quality of the selected studies was
graded independently by two reviewers (SJ and JS) with
the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) tool, a validated tool for the quality assess-
ment of diagnostic accuracy studies[10]. We performed
component analysis using the QUADAS tool which was
depicted as a proportional bar graph for each of the 14
individual criteria. Disagreement between the two
extracting authors was resolved by consensus.
The following variables were extracted from each
study: publication year; country of origin of study; study
design; patient demographics and co-morbidities;
NT-pro-BNP assay type; numbers of true-positive, false-
negative, true-negative, and false-positive observations;
correlation statistic between pleural fluid and serum
NT-pro-BNP if available; and the reference standard
used.
We used the bivariate model for diagnostic meta-
analysis to obtain an overall sensitivity and an overall
specificity[11]. Instead of using the diagnostic odds
ratio, as used in conventional diagnostic meta-analysis
[12], the bivariate model uses pairs of sensitivity and
specificity as the starting point of the analysis. In addi-
tion to accounting for study size, the bivariate model
estimates and incorporates the negative correlation that
may arise between the sensitivity and specificity of the
index test within studies as a result of differences in test
threshold between studies. The bivariate model uses a
random effects approach for both sensitivity and specifi-
city, which allows for heterogeneity beyond chance as a
result of clinical and methodological differences between
studies. The pooled estimates of sensitivity and specifi-
city were used to calculate the average positive and
negative likelihood ratios. Publication bias through small
study effects was assessed with a regression test on the
diagnostic odds ratio[13].
A receiver operating characteristic graph, with the
y-axis representing the index test’s sensitivity (true posi-
tive rate) and the x-axis representing 1-specificity (false
negative rate), was used to plot the individual and sum-
mary points of sensitivity and specificity. Furthermore,
around the pooled estimates, we also plotted a 95% con-
fidence region and a 95% prediction region to illustrate
the precision with which the pooled values were esti-
mated (confidence ellipse of a mean) and to show the
amount of between study variation (prediction ellipse;
the likely range of values for a new study). We used
Stata intercooled version 10.1 (StataCorp, College Sta-
tion, Texas), in particular the midas and metandi com-
mands, for all statistical analyses[14,15].
Results
Our search yielded 128 citations of which 117 were
excluded for various reasons based on the title and
abstract (Figure 1). Eleven were then retrieved for full
text review of which three were excluded because BNP
instead of NT-pro-BNP was used as the biomarker (Fig-
ure 1). Ten studies were included in the final analysis
[16-25]. One study, by Seyhan et al[22], was initially
published online and then was retracted by the editors
of the journal. The reason for retraction was due to a
violation of the journal’s Information for Authors. There-
fore, only the abstract was available for data extraction
and a quality assessment was not possible.
The studies were published from 2004 to 2010. The
majority of the studies (7/9)[16-19,22-24] were done in
Europe whereas two were done in North America[20,25]
and one in Asia[21]. All studies except for two (Porcel
et el[23] and Long et al[25]) were of prospective design
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et al[20] and Long et al[25]) used an electrochemical
luminescence immunoassay (ELCIA) performed on the
Elecsys 2010 analyzer (Roche) to measure levels of NT-
pro-BNP whereas Liao et al[20] and Long et al[25] used
an enzyme-linked immunosorbent assay (ELISA) (Table
1). A total of 1120 patients/pleural effusions were
included in this analysis (429 of cardiac origin and 691
of non-cardiac origin). The control group (non-cardiac
pleural effusions) consisted of mainly malignant pleural
effusions and infections (Table 1).
As there is no gold standard for effusions of cardiac
origin, clinical criteria was used as the reference stan-
dard. All studies used some combination of the follow-
ing criteria: history, physical exam, chest x-ray,
electrocardiogram, echocardiogram, and response to
Figure 1 Flow chart of the studies included in the meta-analysis.
Table 1 Characteristics of the studies included in the meta-analysis.
Study Year Country Design Assay Type Reference Standard Control Group
†
Tomcsanyi et al [16] 2004 Hungary PC ECLIA(1)
‡ Clinical Criteria*
a, b, c, e
57% M; 14% I; 29% O
Porcel et al [17] 2004 Spain PC ECLIA(1) Clinical Criteria*
a, b, c, d, e, f
NR
Kolditz et al [18] 2006 Germany PC ECLIA(1) Clinical Criteria*
a, b, c, e, f
59% M; 21% I; 30% O
Porcel et al [19] 2007 Spain PC ECLIA(1) Clinical Criteria*
a, b, c, d, e, f
48% M; 20% I; 32% O
Liao et al [20] 2008 USA PC ELISA Clinical Criteria*
a, c, e
25% M; 0% I; 75% O
Han et al [21] 2008 Korea PC ECLIA(1) Clinical Criteria*
a, b, e, f
24% M; 66% I; 10% O
Seyhan et al [22] 2009 Turkey PC ECLIA Clinical Criteria*
N/A
N/A
Porcel et al [23] 2009 Spain RC ECLIA(2) Clinical Criteria*
a, b, c, e, f
44% M; 29% I; 27% O
Bayram et al [24] 2009 Turkey PC ECLIA(1) Clinical Criteria*
a, b, c, e, f
23% M; 31% I; 46% O
Long et al [25] 2010 USA RC ELISA Clinical Criteria*
a, b, c, e
25% M; 25% I; 25% O
* = heart failure diagnosis based on (a) history, or (b) physical exam, or (c) chest x-ray, or (d) electrocardiogram, or (e) echocardiogram, or (f) response to
diuretics; † = non-cardiac effusions; ‡ = generation of assay (one or two); ECLIA = electrochemical luminescence immunoassay; ELISA = enzyme-linked
immunosorbent assay; I = infectious effusion; M = malignant effusion; N/A = not available; NR = not recorded; O = other causes (i.e. connective tissue disease,
pleuritis, post-CABG, hepatic hydrothorax, pulmonary embolism, etc); PC = prospective cohort; RC = retrospective cohort;
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York Heart Classification for the patients with effusions
of cardiac origin, all patients were either class III or IV.
Overall, the quality of the reported studies was good
(Figure 2). Five studies[16,19,20,23,25] maybe subject to
spectrum bias as their method of recruitment of patients
consisted of recruiting a target group (patients with
pleural effusions of cardiac origin) and a control group
(patients with pleural effusions of non-cardiac origin)
rather than applying the index and reference test to an
unselected patient population with pleural effusions.
Most studies may be subject to review bias as it was
unclear in eight studies whether the investigators who
used the reference test (clinical criteria) were blinded to
the results of the NT-pro-BNP assay and six studies
[16,18,20,21,24,25] did not state whether the laboratory
personnel performing the index test (NT-pro-BNP
assay) were blinded to the clinical diagnosis.
The average NT-pro-BNP level for nine of the ten studies
was 6140 pg/mL in pleural effusions of cardiac origin (this
value was not available for one study[22]). Of the five stu-
dies[16,18,19,21,24] that analyzed both serum and pleural
fluid NT-pro-BNP levels, all five studies showed high corre-
lation between these two parameters (Table 2). Table 2 also
shows that the percentage of cardiac effusions misclassified
as exudates by Light’s criteria was relatively modest (range
7%-36%) within various studies. However, when these mis-
classified effusions from Light’s criteria were analyzed by
NT-pro-BNP levels, the absolute number of misclassified
effusions was significantly reduced (Table 2).
The pooled sensitivity and specificity of all studies
combined was 94% (95% CI: 90-97) and 94% (95% CI:
89-97) respectively (Figure 3). The pooled positive likeli-
hood ratio was 15.2 (95% CI: 8.1-28.7) and the pooled
negative likelihood ratio was 0.06 (95% CI: 0.03-0.11).
The area under the ROC curve was 0.98 (95% CI: 0.96-
0.99) and the diagnostic odds ratio was 246 (95% CI:
81-745). Figure 4 shows the summary receiver operating
characteristic graph with 95% confidence region and
95% prediction region for NT-pro-BNP.
The between study variability (i.e. heterogeneity)
beyond what could be expected by sampling error was
moderate with an I
2 of 40% (p = 0.09) for the sensitivity
results and high with an I
2 of 84% (p < 0.01) for the
Figure 2 Proportion of all 14 Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool criteria that were fulfilled for seven of
eight studies included in the meta-analysis.
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that this heterogeneity is completely (100%) explained
by threshold effect. Analysis of small study effects,
potentially a result of publication bias, yielded no signifi-
cant evidence for such effects with a p value of 0.26 and
a funnel plot that was fairly symmetrical (Figure 5).
Figure 6 illustrates the post-test probabilities based on
various pre-test probabilities using a Fagan nomogram.
Discussion and Conclusion
Pleural effusions are relatively common in medical prac-
tice. It is estimated that the annual incidence of pleural
effusions in the United States (US) is 1.5 million cases
[26]. The most common cause of pleural effusions is
CHF with an estimated incidence of 500,000 cases in
the US per year[2]. Identifying the underlying etiology
of pleural effusions requires a combination of strategies
including clinical history, pleural fluid analysis, and
potentially more invasive procedures such as pleural tis-
sue biopsy. Clinical history is very important in the diag-
nosis of pleural effusions from a cardiac origin.
However, alone, it does not appear to be very accurate.
Romero-Candeira et al[27] studied 64 patients with
transudative pleural effusions of which 44 were due to
CHF and showed that in 40% of cases initial clinical his-
tory failed to correctly classify the effusion. Pleural fluid
analysis using Light’s criteria is better than clinical
history for diagnosing pleural effusions of cardiac origin
however these criteria misclassify transudates as exuda-
tive effusions approximately 25% of the time, mainly
related to the use of diuretics[2]. Misclassification of
transudates to exudates can lead to inappropriate man-
agement or potentially more invasive diagnostic investi-
gations resulting in increased morbidity and health care
costs. As a result, tests with higher diagnostic accuracy
may prove beneficial in terms of reducing morbidity and
improving cost-efficiency for diagnosing pleural effu-
sions of cardiac origin.
In the last decade several studies have been reported
assessing the diagnostic utility of pleural fluid NT-pro-
BNP in pleural effusions of cardiac origin. To summar-
ize these studies, we conducted a systematic review and
meta-analysis. We included ten studies, of which seven
were from Europe, with a total of 1120 patients and/or
pleural effusions. We showed that the pooled sensitivity
and specificity were identical (94% [95% CI: 90-97] and
94% [95% CI: 89-97]) with a diagnostic odds ratio of
246 (95% CI: 81-745). When the study by Seyhan et al
[22], which was retracted from the literature, was
excluded from the analysis, the sensitivity, specificity,
and diagnostic odds ratio remained the same within
95% confidence intervals.
The quality of the studies was generally good overall.
The main limitations of the studies were the possibility
Table 2 Diagnostic accuracy variables of the studies included in the meta-analysis.
Study No.
Pts/
Pes
TP FN TN FP Se Sp NT-pro-BNP
Threshold*
Average
NT-pro-
BNP
†
Misclassification Correlation
Statistic
∏
Light’s
‡ NT-pro-
BNP
§
Tomcsanyi et al
[16]
28 14 0 14 0 100% 100% ≥ 599
¶ 8236 1/14
(7%)
0/1 R
2 = 0.95
p < 0.0001
Porcel et al[17] 117 40 4 68 5 91% 93% ≥ 1500 6931 10/35
(29%)
2/10 NR
Kolditz et al[18] 93 23 2 63 5 92% 93% ≥ 4000 10427 9/25
(36%)
0/9 S = 0.96
p < 0.001
Porcel et al[19] 93 49 4 35 5 92% 87% ≥ 1500 6106 8/53
(15%)
2/8 S = 0.96
p < 0.001
Liao et al[20] 40 10 0 29 1 100% 97% ≥ 2220 5390 NR NR NR
Han et al[21] 240 81 1 156 2 99% 99% ≥ 1714 3310 28/82
(34%)
1/28 R
2 = 0.93
p < 0.001
Seyhan et al[22] 115 47 4 61 3 92% 95% ≥ 1092 N/A 17/51
(33%)
N/A N/A
Porcel et al[23] 181 84 6 81 10 93% 89% ≥ 1500 6203 20/90
(22%)
4/20 NR
Bayram et al[24] 133 48 3 78 4 94% 95% ≥ 925 4468 19/51
(37%)
0/19 R
2 = 0.91
p < 0.001
Long et al[25] 80 16 4 44 16 80% 73% ≥ 2000 4189 NR NR NR
* = pleural fluid NT-pro-BNP threshold in pg/mL; † = average pleural fluid NT-pro-BNP in CHF effusions in pg/mL; ‡ = misclassification of CHF effusions as
exudates by Light’s criteria; § = misclassification of the CHF effusions already misclassified by Light’s criteria now misclassified by NT-pro-BNP; ∏ = correlation
between serum and pleural fluid NT-pro-BNP levels; ¶ = threshold from 599 to 1457 pg/mL resulted in 100% sensitivity and specificity; N/A = not available
because only abstract available for data extraction; No. = number; NR = not recorded; Pes = pleural effusions; Pts = patients; R
2 = Pearson coefficient of
correlation; S = Spearman’s coefficient of rank correlation; Se = sensitivity; Sp = specificity.
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Page 5 of 11of spectrum bias, review bias, and population bias. Spec-
trum bias refers to distortions in a diagnostic test’sp e r -
formance caused by a distortion in the study population.
Testing is not done across a population with the
expected distribution of disease severity, but rather lim-
ited subsets[28]. In our meta-analysis, five studies
[16,19,20,23,25] acquired their study population by
selecting CHF patients and patients with pleural effu-
sions of non-cardiac origin (control group). The pre-
sence of spectrum bias can lead to an overestimation of
the sensitivity and specificity of the test[28]. Review bias
refers to a situation where persons interpreting the
index test have knowledge of the reference standard or
vice versa, when persons interpreting the reference stan-
dard have knowledge of the index test[29]. In our meta-
analysis, it was very unclear whether this did or did not
occur because the majority of the studies did not report
whether blinding during testing was done. Again, this
may have lead to an overestimation of the diagnostic
performance of the test. Finally, population bias refers
to the generalizability of the diagnostic test to a wider
population[30]. The studies included in our meta-
analysis had poor reporting of any co-morbid conditions
within the CHF-associated pleural effusion group thus
potentially limiting generalizability. Furthermore, a thor-
acentesis in patients with a high pre-test probability for
a cardiac origin of the pleural effusion with low prob-
ability for other causes would not usually be indicated
in most clinical scenarios thus further limiting the gen-
eralizability of these results.
Heterogeneity was moderate for the sensitivity results
and high for the specificity results (Figure 3). In the
summary receiver operating characteristic graph (Figure
4), all but three of the ten ‘sensitivity - (1-specificity)’
combinations of the individual studies lie on or near the
summary receiver operating characteristic curve. This
indicates that studies with a higher sensitivity have
lower specificity and vice versa. This pattern is com-
monly attributed to differences in the threshold level for
test positivity used in different studies[12]. As a result,
the heterogeneity between the studies could well be
explained by threshold level differences between the stu-
dies which ranged from 599 to 4000 pg/mL. Another
potential cause for the heterogeneity may be due to the
various types of clinical criteria used for the reference
standard (Table 1) as there is no gold standard for the
Figure 3 Forrest plot of the sensitivity and specificity of each individual study, pooled sensitivity and specificity, and I
2 statistic for
heterogeneity.
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Page 6 of 11diagnosis of pleural effusions from a cardiac origin. The
most objective criteria for heart failure is echocardiogra-
phy and all studies except for Seyhan et al[22] used this
parameter and of those studies, the majority defined
CHF as an ejection fraction ≤ 40%. Furthermore, of the
studies that reported New York Heart Class, the CHF-
associated pleural effusion patients were of New York
Heart Class (NYHC) III or IV. The control group
among the various studies differed and potentially could
have contributed to the heterogeneity of the results as
well. Malignant pleural effusions and parapneumonic
effusions were the main groups that comprised the con-
trol groups but some studies did have other causes as a
majority of the control group such as connective tissue
disease, pleuritis, post-CABG, hepatic hydrothorax, and
pulmonary embolism. Finally, eight of the ten studies
used electrochemical luminescence immunoassay
(ECLIA) for measuring NT-pro-BNP (8 studies genera-
tion one, one study generation two, one study unknown
generation) while two studies used ELISA which may
have added to the heterogeneity of results as well.
ECLIA uses a non-competitive immunoassay that pro-
duces luminescence via an electrochemical reaction and
compared to ELISA, is faster and more precise[31]. The
ELISA kit from Biomedica has been compared to the
ECLIA kit from Roche Diagnostics revealing significant
disparity of results between the two types of assays[31].
The Roche Diagnostics assay (ECLIA) has dual antibo-
dies targeting two different areas of the NT-pro-BNP
molecule whereas the Biomedica assay (ELISA) only has
a single antibody targeting one region. This may result
in better recognition of NT-pro-BNP and hence better
diagnostic accuracy for the Roche Diagnostics assay.
Furthermore, the cut-off values for serum NT-pro-BNP
a r e1 0f o l dh i g h e ru s i n gt h eB i o m e d i c aa s s a y( E L I S A )
compared to the Roche Diagnostics assay (ECLIA)[31]
which may have also added to the heterogeneity of the
results.
The correlation between pleural fluid and serum levels
of NT-pro-BNP are high as shown by five studies
[16,18,19,21,24] in our meta-analysis (Table 2). This
suggests that thoracentesis could potentially be avoided
Figure 4 Summary receiver operating characteristic graph with 95% confidence region and 95% prediction region for NT-pro-BNP.
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NT-pro-BNP, and no suspicion for a co-existing cause
of the pleural effusion.
Most institutions use BNP to diagnose CHF. Three stu-
dies[23,25,32] have examined the diagnostic accuracy of
BNP for pleural effusions of cardiac origin. The first
study[32] of 57 patients showed a sensitivity of 97% and a
specificity of 89% for plasma BNP. The second study by
Porcel et al[23] (181 patients), showed a sensitivity of
74% and specificity of 92% for pleural fluid BNP and also
showed that the area under the curve (AUC) for NT-pro-
BNP was higher than for pleural fluid BNP, 0.96 (95% CI:
0.94-0.99) vs 0.90 (95% CI: 0.86-0.95) respectively. Corre-
lation between pleural fluid NT-pro-BNP levels and BNP
levels was good, r = 0.78 (p < 0.001). The conclusion
from this study was to use NT-pro-BNP rather than BNP
for diagnosing pleural effusions of cardiac origin because
of the diagnostic superiority of NT-pro-BNP versus BNP,
greater in-vitro stability of NT-pro-BNP compared with
BNP, and longer half-life of NT-pro-BNP (1-2 hours)
compared with BNP (20 minutes). The last study by
Long et al[25] (80 patients) showed that the AUC for
NT-pro-BNP was greater than for pleural fluid BNP, 0.84
(95% CI: 0.72-0.95) vs 0.70 (95% CI: 0.57-0.83). Correla-
tion between pleural fluid NT-pro-BNP and BNP levels
was also good but less impressive, r = 0.57 (p < 0.001),
and only explained 32% of the variance in NT-pro-BNP.
T h ec o n c l u s i o nf r o mt h i ss t u d yw a st h a tN T - p r o - B N P
was a more stable molecule after sample processing and
could be maintained for a greater duration in an in vitro
setting compared to BNP and furthermore because of the
higher diagnostic accuracy of NT-pro-BNP, NT-pro-BNP
should be used over BNP to distinguish pleural effusions
of cardiac origin in select patient populations.
It is difficult to suggest a threshold level for pleural
fluid NT-pro-BNP since the studies used varying thresh-
old levels. The average pleural fluid NT-pro-BNP level
in the studies was 6140 pg/mL. Six of the studies
[16,17,19,21,23,24] used a threshold level between 1457
to 1714 pg/mL (sensitivity and specificity for a threshold
l e v e lo f1 4 5 7p g / m Lb yR O Ca n a l y s i si nt h es t u d yb y
Bayram et al[24] was 84% and 98%, respectively). The
pooled sensitivity and specificity of these six studies is
95% (95% CI: 91-98) and 95% (95% CI: 89-98),
Figure 5 Deeks’ funnel plot asymmetry test for publication bias.
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101-1351). As a result, a threshold level of approxi-
mately ≥ 1500 pg/mL provides very good diagnostic
accuracy for pleural fluid NT-pro-BNP.
The utility of NT-pro-BNP for the diagnosis of pleural
effusions of cardiac origin can be applied to several clinical
situations. First, if the pre-test probability of a pleural effu-
sion due to heart failure is high and alternative diagnoses
are less likely, then a thoracentesis can be avoided and an
elevated serum NT-pro-BNP level will be diagnostic for a
cardiac origin of the pleural effusion. Second, if the pre-
test probability of a pleural effusion due to heart failure is
low or alternative diagnoses are considered in addition to
heart failure, then a thoracentesis should be performed
and if the pleural fluid NT-pro-BNP level is high then this
would be diagnostic of heart failure as one potential cause
for the pleural effusion. Furthermore, in undiagnosed
pleural effusions, for example when Light’s criteria mis-
classify transudative CHF ef f u s i o n sa se x u d a t e sa n dt h e
pre-test probability is equivocal for CHF, a high pleural
fluid NT-pro-BNP would also be diagnostic.
The results of our meta-analysis are corroborated by
another meta-analysis done by Zhou et al[33]. They
included eight studies and found that the sensitivity and
Figure 6 Fagan’s nomogram for NT-pro-BNP illustrating post-test probability with a fixed pre-test probability of 20% for a pleural
effusion of cardiac origin.
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Page 9 of 11specificity for NT-pro-BNP for pleural effusions of car-
diac origin was 95% (95% CI: 92-97) and 94% (95% CI:
92-96), respectively, with a diagnostic odds ratio of 214
(95% CI: 123-374). Based on their meta-analysis, Zhou
et al[ 3 3 ]c o n c l u d e dt h a tp l e u r a lf l u i dN T - p r o - B N Ph a s
high diagnostic accuracy for differentiating cardiac from
non-cardiac conditions in patients presenting with
pleural effusions.
In summary, misclassification of pleural effusions of
cardiac origin can lead to increased morbidity from
further invasive testing and increased health care costs.
Clinical history and pleural fluid analysis with Light’s
criteria may not have sufficient diagnostic accuracy to
diagnose these effusions in certain clinical circum-
stances. Although there is some heterogeneity within
this analysis, we conclude that where the diagnosis of
pleural effusion of cardiac origin is under contempla-
tion, pleural fluid NT-pro-BNP is a useful biomarker
with high diagnostic accuracy.
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